Racial disparities in survival trends in patients with metastatic Hormone receptor positive/Her 2 negative breast cancer: a SEER population-based study

被引：0
|
作者：
Soto, Alvaro Alvarez
Bernal, Ana Maria
Mesias, Jesus Anampa
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-03-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-03-21
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program
    Li, Juanjuan
    Xia, Yue
    Wu, Qi
    Zhu, Shan
    Chen, Chuang
    Yang, Wen
    Wei, Wen
    Sun, Shengrong
    ONCOTARGET, 2017, 8 (30) : 49370 - 49379
  • [22] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Calvani, Nicola
    Caliolo, Chiara
    Quaranta, Annamaria
    Nacci, Angelo
    Cinieri, Saverio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 291 - 301
  • [23] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [24] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
  • [25] Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
    Hope S. Rugo
    Adam M. Brufsky
    Marianne Ulcickas Yood
    Debu Tripathy
    Peter A. Kaufman
    Musa Mayer
    Bongin Yoo
    Oyewale O. Abidoye
    Denise A. Yardley
    Breast Cancer Research and Treatment, 2013, 141 : 461 - 470
  • [26] Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
    Rugo, Hope S.
    Brufsky, Adam M.
    Yood, Marianne Ulcickas
    Tripathy, Debu
    Kaufman, Peter A.
    Mayer, Musa
    Yoo, Bongin
    Abidoye, Oyewale O.
    Yardley, Denise A.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) : 461 - 470
  • [27] Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer
    Osborne, Cynthia
    Challagalla, Jagathi D.
    Eisenbeis, Charles F.
    Holmes, Frankie Ann
    Neubauer, Marcus A.
    Koutrelakos, Nicholas W.
    Taboada, Carlos A.
    Vukelja, Sasha J.
    Wilks, Sharon T.
    Allison, Mary Ann
    Reddy, Praveen
    Sedlacek, Scot
    Wang, Yunfei
    Asmar, Lina
    O'Shaughnessy, Joyce
    CLINICAL BREAST CANCER, 2018, 18 (01) : E89 - E95
  • [28] Chemotherapy Treatment and Survival in Estrogen Receptor Negative Metastatic Breast Cancer: A Population-Based Analysis
    Zuckerman, I. H.
    Schneider, M.
    Onukwugha, E.
    McNally, D. L.
    Gardner, J. F.
    Pandya, N.
    Seal, B.
    Mullins, C. D.
    CANCER RESEARCH, 2009, 69 (24) : 613S - 614S
  • [29] A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
    Chan, Nancy
    Moore, Dirk
    Tandra, Pavankumar
    Rana, Jatin
    Omene, Coral
    George, Mridula
    Krishnamurthy, Jairam
    Desai, Shruti
    Patel, Nayana
    Wang, Yue
    Bicomong, Marc
    Tan, Xiao-Wei
    Hirshfield, Kim
    Ganesan, Shridar
    Toppmeyer, Deborah
    CANCER RESEARCH, 2022, 82 (04)
  • [30] Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
    Abdelmaksoud, Bader A.
    Toam, Mostafa M.
    Fayed, Alaa A.
    BREAST CANCER MANAGEMENT, 2019, 8 (03)
12345